Sign In
Buy NVO
$47.64
+0.230 (+0.485%)
At Close: Jun 25, 2026
Ozempic Receives FDA Approval To Treat Kidney Disease
05:50pm, Tuesday, 28'th Jan 2025
The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S NVO, for the treatment of chronic kidney disease in patients who also have type 2 diabetes.
Shareholders that lost money on Novo Nordisk A/S(NVO) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
05:30pm, Tuesday, 28'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws, fol
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit
05:00pm, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action on behalf of purchasers of securities of Novo Nordisk A/S (NY
Shareholders that lost money on Novo Nordisk A/S(NVO) should contact Levi & Korsinsky about pending Class Action - NVO
04:30pm, Tuesday, 28'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - NVO
03:45pm, Tuesday, 28'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities laws
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug's Latest Approval
03:40pm, Tuesday, 28'th Jan 2025
The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk's popular drug known for diabetes and
NVO Investor Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Novo Nordisk A/S
03:19pm, Tuesday, 28'th Jan 2025
Robbins LLP is Investigating Allegations that Novo Nordisk A/S (NVO) Misled Investors Regarding REDEFINE-1, Novo's Phase 3 CagriSema Study on Obesity
US FDA approves Novo Nordisk's diabetes drug to reduce risk of worsening kidney disease
02:39pm, Tuesday, 28'th Jan 2025
Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney disease and death due to cardiovascular disease in adults with type 2 diabetes a
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding its use
02:34pm, Tuesday, 28'th Jan 2025
The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA's decisi
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in Novo Lawsuit - NVO
01:00pm, Tuesday, 28'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a potential recovery under the federal securities
How to Play NVO Stock After New Drug's Success in Obesity Study
12:30pm, Tuesday, 28'th Jan 2025
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Novo Nor
What Does the Future Hold for Eli Lilly?
08:45am, Tuesday, 28'th Jan 2025
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S NYSE: NVO were likely the hottest medical sector story in 2024. With its offering of tirzepatide (b
Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before March 25, 2025 to Discuss Your Rights - NVO
05:45am, Tuesday, 28'th Jan 2025
NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit. CLASS DEFINITION: The
